Summary
Becton, Dickinson and Company (BDX) announced a change to its Board of Directors with the election of Carrie L. Byington, M.D., effective October 21, 2021. Dr. Byington's appointment is noteworthy as she brings external expertise to the board and will contribute to key committees. Dr. Byington's addition strengthens the board's oversight capabilities, particularly within the Audit Committee and the Quality and Regulatory Committee. Her independence, as determined by NYSE rules and BD's own governance principles, ensures an objective perspective. Investors should note that her compensation for this role will be in line with existing non-management director compensation practices, with an initial grant of restricted stock units.
Key Highlights
- 1Carrie L. Byington, M.D. has been elected to the Becton Dickinson (BD) Board of Directors, effective October 21, 2021.
- 2Dr. Byington will serve as a member of both the Audit Committee and the Quality and Regulatory Committee.
- 3The Board of Directors has determined Dr. Byington to be independent under NYSE rules and BD's Corporate Governance Principles.
- 4Dr. Byington's appointment brings additional expertise to the board's oversight functions.
- 5Her compensation will follow the established structure for non-management directors.
- 6She will receive restricted stock units valued at $54,969 as a prorated grant.